Therapeutic Modalities | Industry Spotlights & Insight Articles
Bispecific Antibody Format: Interview with Laura von Schantz, Chief Technology Officer, Alligator Biosciences
Talking with Laura von Schantz, Chief Technology Officer, at Alligator Biosciences about their RUBY bispecific antibody format.
More on antibody based therapies:
- European Commission Approves Genmab’s Subcutaneous Bispecific Antibody Tepkinly
- Another Partnership from Takeda and F-Star Therapeutics to Look for Antibody-Based Therapies
- Monoclonal Antibodies: Guided Missiles in the Battle Against Cancer and More
Also check out our flagship Immuno Conference: A two-day event packed with leading speakers, research and cutting-edge presentations on the latest advancements in the discovery & development of cancer immunotherapies with dedicated sessions on different therapeutic modalities, biomarkers, precision and omics-based approaches in IO as well as case studies on innovative preclinical and translational tools.
